Literature DB >> 16075929

An 88-year-old woman diagnosed with adrenal tumor and congenital adrenal hyperplasia: connection or coincidence?

H Falhammar1, M Thorén.   

Abstract

An 88-yr-old woman presented with a 3x4x5 cm adrenal incidentaloma. Apart from partial cortisol deficiency there were no clinical or laboratory signs of abnormal hormone production. Because of suspicion of carcinoma, a urinary steroid profile was carried out which indicated 21-hydroxylase deficiency with elevated pregnantriol. Biopsy of the tumor showed benign adenoma tissue. The genetic analysis showed two mutations in the CYP21-gene, V281L and 1172N consistent with mild non-classic congenital adrenal hyperplasia (CAH). The patient showed a general improvement with a low prednisolone dose. Previous reports have shown increased prevalence of CAH in patients with adrenal tumors although, to our knowledge, no one has reported the combination in a patient as old as in ours. Thus, clinical signs and symptoms of CAH should be looked for in patients with adrenal incidentalomas, even in the very old ones, and if suspicion further diagnostic work-up should be carried out to provide adequate treatment and follow-up.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16075929     DOI: 10.1007/bf03347226

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  30 in total

1.  Adrenal nodules in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: regression after adequate hormonal control.

Authors:  L R Giacaglia; B B Mendonca; G Madureira; K F Melo; C A Suslik; I J Arnhold; T A Bachega
Journal:  J Pediatr Endocrinol Metab       Date:  2001-04       Impact factor: 1.634

Review 2.  Adrenal mass.

Authors:  D M Cook
Journal:  Endocrinol Metab Clin North Am       Date:  1997-12       Impact factor: 4.741

Review 3.  Basic and clinical aspects of congenital adrenal hyperplasia.

Authors:  M I New
Journal:  J Steroid Biochem       Date:  1987       Impact factor: 4.292

4.  Virilizing adrenocortical carcinoma. Development in a patient with salt-losing congenital adrenal hyperplasia.

Authors:  A Bauman; C G Bauman
Journal:  JAMA       Date:  1982-12-17       Impact factor: 56.272

5.  21-Hydroxylase deficiency presenting as massive bilateral adrenal masses in the seventh decade of life.

Authors:  K Abo; K Sumino; H Nishio; T Hozumi; Y Ishida; K Fujieda; T Tajima; T Kazumi
Journal:  Endocr J       Date:  1999-12       Impact factor: 2.349

6.  Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism.

Authors:  E S Knochenhauer; C Cortet-Rudelli; R D Cunnigham; B A Conway-Myers; D Dewailly; R Azziz
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

7.  Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden.

Authors:  A Thil'en; A Nordenström; L Hagenfeldt; U von Döbeln; C Guthenberg; A Larsson
Journal:  Pediatrics       Date:  1998-04       Impact factor: 7.124

8.  Testicular adrenal rest tumours in postpubertal males with congenital adrenal hyperplasia: sonographic and MR features.

Authors:  Nike M M L Stikkelbroeck; Harold M Suliman; Barto J Otten; Ad R M M Hermus; Johan G Blickman; Gerrit J Jager
Journal:  Eur Radiol       Date:  2003-01-18       Impact factor: 5.315

9.  Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia.

Authors:  S Jaresch; E Kornely; H K Kley; R Schlaghecke
Journal:  J Clin Endocrinol Metab       Date:  1992-03       Impact factor: 5.958

10.  Steroid 21-hydroxylase mutations and 21-hydroxylase messenger ribonucleic acid expression in human adrenocortical tumors.

Authors:  F Beuschlein; E Schulze; P Mora; H P Gensheimer; C Maser-Gluth; B Allolio; M Reincke
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958

View more
  9 in total

1.  Non-functioning adrenal incidentalomas caused by 21-hydroxylase deficiency or carrier status?

Authors:  Henrik Falhammar
Journal:  Endocrine       Date:  2014-01-23       Impact factor: 3.633

Review 2.  Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency.

Authors:  Krupali Bulsari; Henrik Falhammar
Journal:  Endocrine       Date:  2016-12-07       Impact factor: 3.633

Review 3.  Clinical outcomes in the management of congenital adrenal hyperplasia.

Authors:  Henrik Falhammar; Marja Thorén
Journal:  Endocrine       Date:  2012-01-07       Impact factor: 3.633

Review 4.  Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome.

Authors:  Henrik Falhammar; Anna Nordenström
Journal:  Endocrine       Date:  2015-06-17       Impact factor: 3.633

5.  Nonclassic congenital adrenal hyperplasia.

Authors:  Selma Feldman Witchel; Ricardo Azziz
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-30

Review 6.  Biochemical and genetic diagnosis of 21-hydroxylase deficiency.

Authors:  Henrik Falhammar; Anna Wedell; Anna Nordenström
Journal:  Endocrine       Date:  2015-09-04       Impact factor: 3.633

7.  A 31-year-old woman with infertility and polycystic ovaries diagnosed with non-classic congenital adrenal hyperplasia due to a novel CYP21 mutation.

Authors:  H Falhammar; M Thorén; K Hagenfeldt
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

Review 8.  The role of 21-hydroxylase in the pathogenesis of adrenal masses: review of the literature and focus on our own experience.

Authors:  L Barzon; P Maffei; N Sonino; C Pilon; L Baldazzi; A Balsamo; O Del Maschio; G Masi; M Trevisan; M Pacenti; F Fallo
Journal:  J Endocrinol Invest       Date:  2007 Jul-Aug       Impact factor: 4.256

9.  Adrenocortical cancer: mortality, hormone secretion, proliferation and urine steroids - experience from a single centre spanning three decades.

Authors:  Jan Calissendorff; Freja Calissendorff; Henrik Falhammar
Journal:  BMC Endocr Disord       Date:  2016-03-17       Impact factor: 2.763

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.